MMA FREE Webinar Series - Why med-tech firms, venture capitalists and bankers are investing in psychedelic medicine

Don’t miss out - Get your tickets early!

Join this FREE, 60-minute online webinar to gain access to insights and learn about ground breaking treatments to chronic mental health conditions.

Global interest and investment in psychedelic medicine companies is accelerating. However, these treatments are not like typical medicines. The patient experience and clinical care model is intense and also deeply, and necessarily, intertwined. So, the question arises, how can we develop care delivery models for these treatments that are safe, effective but also commercially viable? We will explore these themes with clinical service partner Emyria. We will explore how we are approaching these challenges and learn from Emryia’s experience creating an evidence-generating care model for medicinal cannabis.

This FREE webinar will explore:

1. An overview of the psychedelic industry and its growth globally and locally
2. The different types of for-profit commercial entities developing
3. The need for these treatments in Australia and how we are actively preparing for their delivery
4. Importance of working with a therapist the patient can trust and how set/setting play a role
5. How the physical infrastructure of the clinic affects the patient experience. The importance of investing in the healing space
6. The importance of co-creating robust and ethically-sourced clinical data with patients to ensure we learn from every patient

WEBINAR SESSION

Topic: Why med-tech firms, venture capitalists and bankers are investing in psychedelic medicine

Date: Wednesday 10 March 2021

Time: 7:25pm for 7:30pm start – 8:45pm (incl Q&A) (AEDT)

The presentation WILL BEGIN AT 7:30pm.

Location: Online. A link will be emailed to you with the viewing details.

Don’t miss out - Get your tickets early!

Support these events:

Whilst our webinars are free of charge, we strongly encourage you to make a donation and support our important mission of making these therapies available through our medical system. This can be done at the time of reserving your ticket. Please share these events with your networks.

More about Mind Medicine Australia and medicinal psychedelic-assisted therapy

Mind Medicine Australia is Australia’s leading not-for-profit organisation working on the use of medicinal psilocybin and MDMA-assisted therapies to treat a range of mental illnesses. Mind Medicine Australia exists to help alleviate the suffering caused by our accelerating mental illness epidemic in Australia, through expanding the treatment options available to medical practitioners and their patients.

Unlike current treatments such as anti-depressants, which only manage the illness and can have nasty side effects, psilocybin and MDMA assisted therapies have been scientifically proven to be a safe and effective cure for anxiety, depression, end-of-life stress, addictions and PTSD after just a short treatment program. These medicines are also currently being researched for dementia, eating disorders, OCD and a number of other conditions. Both medicines have been granted Breakthrough Therapy Status by the FDA in the USA to fast-track their approval. This designation is only given to medicines which may prove to be vastly superior to existing treatments.

At Mind Medicine Australia we are dedicated to helping the now global movement to spread this awareness and ensure these medicines are available via the medical system. Please watch and share our 2 minute animation to find out why psychedelic-assisted psychotherapy needs to be available to those who are suffering.

More about the presenters

Peter Hunt AM

Founder & Chair of Mind Medicine Australia

As an investment banker Peter Hunt AM advised local and multi-national companies and governments in Australia for nearly 35 years.  He co-founded and was Executive Chairman of one of Australia’s leading investment banking advisory firms, Caliburn Partnership (now called Greenhill Australia) and continued as Chairman of the Firm after its sale to Greenhill Inc in 2009. Peter was a member of the Advisory Panel of ASIC and chaired the Vincent Fairfax Family Office.

Peter is an active philanthropist involved in funding, developing and scaling social sector organisations which seek to create a better and fairer world.  He is Chairman of Mind Medicine Australia which he established with his wife, Tania de Jong, in 2018. He founded Women’s Community Shelter in 2011 and remains on the Board. He is Chairman of So They Can, Grameen Australia and Grameen Australia Philippines. Peter is a Director of Project Rozana and an Advisory Board member of the Monash Sustainable Development Institute. Peter also acts as a pro bono adviser to Creativity Australia. 

Peter was made a member of the General Division of the Order of Australia in the Queen’s Birthday Honours List in 2010 for services to the philanthropic sector.

Dr Michael Winlo

Chief Executive Office and Managing Director, Emyria

Dr Michael Winlo, chief executive of Emerald Clinics since August 2019, was chief executive of Linear Clinical Research for 3 years and remained on the board from July 2019 when he stepped down from the CEO role to lead a startup company in digital health innovation. Linear Clinical Research is the clinical trials arm of the Harry Perkins Institute of Medical Research. Dr Winlo holds a Bachelor of Medicine and Surgery from the University of Western Australia, and an MBA from the Stanford Graduate School of Business. He was a co-founder of medical device startup Cerulean Medical in 2007, and spent five years in the US growing the health practice of data analysis firm Palantir Technologies

Professor Alistair Vickery

Executive Medical Director, Emyria

Alistair is the medical director of Emerald Clinics and has a wealth of expertise in clinical practice, health service management, clinical and educational research and board director skills.  He is adjunct Clinical Professor of Primary Health Care at the University of Western Australia and Notre Dame University and an active specialist general practitioner.  He is the clinical lead of the research group CHASM (The Collaborative for Health Care Analysis and Statistical Modelling) – providing high-level analysis and statistical modelling to inform WA Health clinical service planning and service evaluation. Alistair is Board Chair of Black Swan Health, one of the largest NFP primary health care, disability, and mental health services in Australia. Alistair is a Fellow of the Australasian College of Health Service Management and an AICD graduate.

Can't attend? You can still support MMA and ensure these treatments are available and accessible to those who are suffering!

By donating to Mind Medicine Australia, you will be helping us to accelerate the availability and best practice of psychedelic-assisted psychotherapy in Australia. We are a small organisation doing big things – we need your support.   

Please click here to make a tax-deductible donation. 

Disclaimer

Mind Medicine Australia does not encourage or facilitate illegal use of psychedelics or plant medicines. MMA focus is focused on clinical and legal use only supported by the emerging science and legislative processes. Mind Medicine Australia reserves the right to record and publish webinars on various social media platforms. You agree that you will not discuss any names, locations or specific details of illegal use of psychedelics both verbally or via any written forms of communication via Mind Medicine Australia social media platforms (for example facebook, instagram and zoom private and public chat forms during the webinar). Breaches of these guidelines may result in not being able to participate in the event. We thank you for support and cooperation on these matters.